Table 3.
Cost inputs
| Parameter | Value | References |
|---|---|---|
| Drug costs per daya | ||
| Vericiguat | $19.43 | [24] |
| ACEi or ARB | $0.03 | [24, 25] |
| Beta blockers | $0.05 | [24, 26] |
| Sacubitril/valsartan | $19.43 | [24, 27] |
| MRA | $0.11 | [24, 28] |
| Medical costs | ||
| HF hospitalization costs (per event) | $23,605 | [20, 22] |
| Routine care cost (per month alive) | $307 | [20, 22] |
| Terminal care cost (per mortality event)b | $31,779 | [22, 36] |
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blockers, HF heart failure, MRA mineralocorticoid receptor antagonists
aDetailed drug wholesale acquisition costs and drug dosage used to estimate daily drug costs are shown in [Table S1]
bThe $31,779 applied in base case analysis was based on the direct heart failure-related medical costs in the last 1 month before death [36]